Eisbach Bio: The Munich-based biotech company Eisbach Bio has received a grant from the German Federal Ministry of Education and Research (BMBF) for the clinical development of a COVID-19 drug. Funding of 8 million eurosPreclinical development was recently completed. (Photo: IZB)